Germany Veterinary Healthcare Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Germany Veterinary Healthcare Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Germany Veterinary Healthcare Market is expected to register a CAGR of nearly 4.5% during the forecast period (2022-2027).

The COVID-19 pandemic has brought attention to the ability of veterinary healthcare to adapt and respond to a developing infectious disease as well as its function in preserving animal health and defending general public health. The market under study has benefited from the organization's cooperative efforts to test COVID-19 in animals. The World Veterinary Association (WVA) and regional veterinary organizations in Europe will declare veterinary services to be "essential" in 2020, just like human healthcare services, according to a Health for Animals article. As a result, a large number of veterinarians are still working under the present COVID-19 circumstances. The European Medicines Agency (EMA) has also created and put into effect a few standards to guarantee the accessibility of veterinary medications on the German market. The market under study, however, was negatively impacted by a breakdown in the supply chain and a delay in the delivery of diagnostics equipment, consumables, and reagents during the pandemic in Germany. The market analyzed during a pandemic encountered numerous significant challenges, such as export bans enacted in many nations, bottlenecks in trucking and port inspections delaying deliveries of crucial goods, and a shortage of operational production facilities. As a result, this restraint had a negative effect on the market under investigation. However, later good events contributed to the market study gaining speed, which in turn fueled the market's expansion.

Certain factors that are driving the veterinary healthcare market growth in Germany include advanced technology leading to innovations in animal healthcare, raising awareness, and initiatives by the government, and increasing productivity at the risk of an emerging zoonosis. Throughout the forecast, Germany is anticipated to hold a sizable market share in the European veterinary healthcare sector. The growing trend of pet adoption in the nation is also fueling the expansion of the industry under investigation. For instance, according to the FEDIAF estimate for 2021, Germany has a total pet population of 26,400,000, of which 10,700,000 are dogs and 15,700,000 are cats. According to the aforementioned source, Germany is the European nation with the biggest number of cats and dogs as pets. In Germany, laws and the veterinary administration work together to safeguard animal health. They guarantee good animal husbandry and cleanliness, as well as efficient disease prevention and eradication efforts. It also confirms whether or not animals are given effective, authorized veterinary medicines. Therefore, it is projected that such occurrences will have a favorable effect on market growth in Germany throughout the projection period.

Product launches by key market player is another factor in market growth. Boehringer Ingelheim revealed that the 2.0 version of the FreVAX smartphone app can be used to control the FreVAX intramuscular needle-free device in July 2021. It was developed to improve communication with the FreVAX system, a pig intramuscular needle-free vaccine injection device. Similarly, in May 2019, Germany granted a Supplementary Protection Certificate (SPC) for Galliprant, indicating the control of pain and inflammation associated with osteoarthritis in dogs, developed by Aratana, a subsidiary of Elanco Animal Health. The SPC extends the period of exclusive sales rights for Galliprant until March 1, 2031. The market under study is therefore anticipated to experience significant expansion throughout the forecast period as a result of the aforementioned factors.

However, the increasing cost of animal testing and veterinary services are expected to hinder the market growth.

Key Market TrendsVaccine is Expected to Hold a Significant Share in the Therapeutics Segment Over the Forecast Period

Vaccines comprise viruses, bacteria, or other disease-causing organisms that have been killed or altered so that they cannot cause any disease, boosting immunity. New advanced vaccines have been manufactured containing genetically engineered components derived from those disease agents. To increase their market position, industry companies are concentrating on the introduction of novel vaccinations across Europe. For instance, Boehringer Ingelheim's introduced the VAXXITEK HVT+IBD+ND vaccine in January 2020. This vaccine offers robust immune support and improved defense against Marek's disease, infectious bursal disease (classic and variant kinds), and Newcastle disease.

In a similar vein, Boehringer Ingelheim introduced the porcine parvovirus vaccine in March 2022. For healthy gilts and sows six months and older, ReproCyc ParvoFLEX offers effective and safe protection against reproductive failure brought on by porcine parvovirus. The PREVEXXION RN+HVT+IBD and PREVEXXION RN vaccinations for Marek's disease were introduced by Boehringer Ingelheim in April 2021 in the UK and other EU nations. A novel, practical, and high-performing treatment option, PREVEXXION RN+HVT+IBD combines PREVEXXION RN and VAXXITEK HVT+IBD in a single ampoule. As a result, it is projected that these changes will have a beneficial effect on the market, spurring segment expansion over the projection period.

Competitive Landscape

The German veterinary Healthcare market is moderately competitive and consists of a number of major players. Companies like Boehringer Ingelheim International GmbH, Ceva Animal Health Inc, Elanco Animal Health, Idexx Laboratories, Merck & Co. Inc., Phibro Animal Health, Randox Laboratories, Ltd, Vetoquinol GmbH, Virbac SA, Zoetis, Inc, among others, hold the substantial market share in the Veterinary Healthcare market in Germany.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.